The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults. The updated recommendation calls for a single ...

The good news is that most cases of whooping cough are preventable with DTaP vaccines in childhood and Tdap shots at age 11 ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

Adults diagnosed with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a significantly higher risk of mortality—2.7 times greater—within one ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the ...